NCT07644559Phase 2Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants180Estimated

Source updated2026-09-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS

Treatments or interventions studied

VS-7375Drug
cetuximabDrug

Primary outcomes · main study measures

Read the study measures

measure: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1; description: Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR); timeFrame: 6 months; measure: To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.; description: Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations.; timeFrame: 6 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history